Rizatriptan — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Migraine

• Amitriptyline
• Propranolol
• Sumatriptan
• Topiramate

Other medications in Neurological

• Ropinirole
• Rufinamide
• Selegiline
• Siponimod
• Teriflunomide
• Tiagabine
• Trihexyphenidyl
• Ubrogepant

About Rizatriptan

Rizatriptan is a powerful medication designed to quickly alleviate the debilitating pain of migraine headaches. If you're one of the millions suffering from migraines, understanding your treatment options is crucial. With TheDrugClub, managing your migraines—and your budget—just got easier, offering significant savings on essential prescriptions like rizatriptan.

Rizatriptan is primarily prescribed to treat acute migraine attacks in adults and children aged 6-17 years. It's not intended for preventing migraines or treating other types of headaches. When a migraine strikes, rizatriptan can be a game-changer, quickly reducing severe pain, throbbing, light sensitivity (photophobia), sound sensitivity (phonophobia), and nausea often associated with these debilitating headaches.

Rizatriptan belongs to a class of drugs called triptans, or serotonin receptor agonists. Migraines are thought to be caused, in part, by the dilation of blood vessels in the brain and the release of certain chemicals that cause inflammation and pain. Rizatriptan works by selectively binding to serotonin (5-HT1B/1D) receptors in the brain. This action helps to constrict the dilated blood vessels in the brain that contribute to migraine pain. Additionally, it can block pain signals from being sent along nerves, providing comprehensive relief. It's designed to be taken at the first sign of a migraine attack, offering rapid relief within 30 minutes to 2 hours for many individuals.

Without insurance or a prescription savings program, the cost of rizatriptan can be a significant burden. Prices can vary widely depending on the pharmacy, dosage, and whether you're purchasing the brand-name Maxalt or its generic equivalent

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Rizatriptan is approved for (FDA label)

Ri zatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use • Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. • Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ]. • Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks.

Source: Read the full FDA label on DailyMed. Label effective date: November 26, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rizatriptan (FDA label)

Rizatriptan Benzoate Tablets, USP: • The 5 mg tablets are pale pink, capsule-shaped, compressed tablets debossed with 'CL 33' on one side and plain on the other • The 10 mg tablets are pale pink, capsule-shaped, compressed tablets debossed "CL 34" on one side and plain on the other • Rizatriptan Benzoate Tablets: 5 mg and 10 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: f000d96c-42a0-4aac-96ca-8cef289979ce. SPL document ID: 32eb56b6-9cb6-4ad2-bffb-1cf9af4bfd2d. Label effective date: November 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rizatriptan (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: • Myocardial Ischemia, Myocardial Infarction, and Prinzmetal's Angina [see Warnings and Precautions ( 5.1 )]. • Arrhythmias [see Warnings and Precautions ( 5.2 )]. • Chest, Throat, Neck and/or Jaw Pain/Tightness/Pressure [see Warnings and Precautions ( 5.3 )]. • Cerebrovascular Events [see Warnings and Precautions ( 5.4 )]. • Other Vasospasm Reactions [see Warnings and Precautions ( 5.5 )]. • Medication Overuse Headache [see Warnings and Precautions ( 5.6 )]. • Serotonin Syndrome [see Warnings and Precautions ( 5.7 )]. • Increase in Blood Pressure [see Warnings and Precautions ( 5.8 )]. The most common adverse reactions in adults were (incidence ≥ 5% and greater than placebo): asthenia/fatigue, somnolence, pain/pressure sensation and dizziness (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: f000d96c-42a0-4aac-96ca-8cef289979ce. SPL document ID: 32eb56b6-9cb6-4ad2-bffb-1cf9af4bfd2d. Label effective date: November 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rizatriptan (FDA label)

Rizatriptan benzoate tablets are contraindicated in patients with: • Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1 )]. • Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions ( 5.1 )]. • History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions ( 5.4 )]. • Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 )]. • Ischemic bowel disease [see Warnings and Precautions ( 5.5 )]. • Uncontrolled hypertension [see Warnings and Precautions ( 5.8 )]. • Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.2 and 7.3 )]. • Hemiplegic or basilar migraine [see Indications and Usage ( 1 )]. .

Source: FDA prescribing information (DailyMed). Set ID: f000d96c-42a0-4aac-96ca-8cef289979ce. SPL document ID: 32eb56b6-9cb6-4ad2-bffb-1cf9af4bfd2d. Label effective date: November 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rizatriptan (FDA label)

• Myocardial ischemia, myocardial infarction, and Prinzmetal's angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors ( 5.1 ) • Arrhythmias: Discontinue dosing if occurs ( 5.2 ) • Chest/throat/neck/jaw pain, tightness, pressure, or heaviness; Generally not associated with myocardial ischemia; Evaluate patients at high risk ( 5.3 ) • Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue dosing if occurs ( 5.4 ) • Gastrointestinal ischemic events, peripheral vasospastic reactions: Discontinue dosing if occurs ( 5.5 ) • Medication overuse headache: Detoxification may be necessary ( 5.6 ) • Serotonin syndrome: Discontinue dosing if occurs ( 5.7 ) 5.1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal's Angina Rizatriptan benzoate should not be given to patients with ischemic or vasospastic coronary artery disease. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of rizatriptan benzoate.

Source: FDA prescribing information (DailyMed). Set ID: f000d96c-42a0-4aac-96ca-8cef289979ce. SPL document ID: 32eb56b6-9cb6-4ad2-bffb-1cf9af4bfd2d. Label effective date: November 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rizatriptan (FDA label)

7.1 Propranolol The dose of rizatriptan benzoate should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration ( 2.4 ) and Clinical Pharmacology ( 12.3 )] . 7.2 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.

Source: FDA prescribing information (DailyMed). Set ID: f000d96c-42a0-4aac-96ca-8cef289979ce. SPL document ID: 32eb56b6-9cb6-4ad2-bffb-1cf9af4bfd2d. Label effective date: November 26, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.